期刊
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS
卷 23, 期 -, 页码 427-448出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-genom-120921-103442
关键词
genomics; neonatal intensive care unit; NICU; newborn infants; precision medicine
资金
- National Institutes of Health [U01TR002271, U54TR002359, R01HD101540]
- Rady Children's Hospital
- Takeda
Genetic diseases are a leading cause of neonatal and infant mortality in the United States. Rapid genome sequencing has been developed to improve diagnosis and treatment of these diseases in neonatal intensive care units. It identifies pathogenic genomic variants, changes medical management, and predicts genetic risks.
Genetic diseases disrupt the functionality of an infant's genome during fetal-neonatal adaptation and represent a leading cause of neonatal and infant mortality in the United States. Due to disease acuity, gene locus and allelic heterogeneity, and overlapping and diverse clinical phenotypes, diagnostic genome sequencing in neonatal intensive care units has required the development of methods to shorten turnaround times and improve genomic interpretation. From 2012 to 2021, 31 clinical studies documented the diagnostic and clinical utility of first-tier rapid or ultrarapid whole-genome sequencing through cost-effective identification of pathogenic genomic variants that change medical management, suggest new therapeutic strategies, and refine prognoses. Genomic diagnosis also permits prediction of reproductive recurrence risk for parents and surviving probands. Using implementation science and quality improvement, deployment of a genomic learning healthcare system will contribute to a reduction of neonatal and infant mortality through the integration of genome sequencing into best-practice neonatal intensive care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据